The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to sub
The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.
대표청구항▼
1. A method of treating peanut allergy in a subject susceptible to an anaphylactic allergic response to a peanut allergen protein, the method comprising a step of: administering to the subject via topical, oral, or local administration, a composition comprising: dead E. coli cells that have expresse
1. A method of treating peanut allergy in a subject susceptible to an anaphylactic allergic response to a peanut allergen protein, the method comprising a step of: administering to the subject via topical, oral, or local administration, a composition comprising: dead E. coli cells that have expressed a recombinant version of a modified food allergen protein whose amino acid sequence differs from that of a corresponding wild-type food allergen protein in that at least one IgE epitope has a substitution in the modified food allergen protein such that the modified food allergen protein has a reduced ability to bind to or cross-link IgE as compared with unmodified wild-type food allergen protein, the at least one IgE epitope being one that is recognized when the unmodified wild-type food allergen protein is contacted with serum IgE from an individual that is allergic to the unmodified wild-type food allergen protein, wherein:when unmodified wild-type Ara h 1 protein has the amino acid sequence of SEQ ID NO: 2, the substitution is in an IgE epitope selected from the group consisting of: an epitope found between amino acids 25 and 34 of SEQ ID NO: 2;an epitope found between amino acids 48 and 57 of SEQ ID NO: 2;an epitope found between amino acids 65 and 74 of SEQ ID NO: 2;an epitope found between amino acids 89 and 98 of SEQ ID NO: 2;an epitope found between amino acids 97 and 106 of SEQ ID NO: 2;an epitope found between amino acids 107 and 116 of SEQ ID NO: 2;an epitope found between amino acids 123 and 132 of SEQ ID NO: 2;an epitope found between amino acids 134 and 143 of SEQ ID NO: 2;an epitope found between amino acids 294 and 303 of SEQ ID NO: 2;an epitope found between amino acids 311 and 320 of SEQ ID NO: 2;an epitope found between amino acids 325 and 334 of SEQ ID NO: 2;an epitope found between amino acids 344 and 353 of SEQ ID NO: 2;an epitope found between amino acids 393 and 402 of SEQ ID NO: 2;an epitope found between amino acids 409 and 418 of SEQ ID NO: 2;an epitope found between amino acids 461 and 470 of SEQ ID NO: 2;an epitope found between amino acids 498 and 507 of SEQ ID NO: 2;an epitope found between amino acids 525 and 534 of SEQ ID NO: 2;an epitope found between amino acids 539 and 548 of SEQ ID NO: 2;an epitope found between amino acids 551 and 560 of SEQ ID NO: 2;an epitope found between amino acids 559 and 568 of SEQ ID NO: 2;an epitope found between amino acids 578 and 587 of SEQ ID NO: 2;an epitope found between amino acids 597 and 606 of SEQ ID NO: 2;and a combination thereof; andwhen unmodified wild-type Ara h 2 protein has the amino acid sequence of SEQ ID NO: 4, the substitution is in an IgE epitope selected from the group consisting of: an epitope found between amino acids 15 and 24 of SEQ ID NO: 4;an epitope found between amino acids 21 and 30 of SEQ ID NO: 4;an epitope found between amino acids 27 and 36 of SEQ ID NO: 4;an epitope found between amino acids 39 and 48 of SEQ ID NO: 4;an epitope found between amino acids 49 and 58 of SEQ ID NO: 4;an epitope found between amino acids 57 and 66 of SEQ ID NO: 4;an epitope found between amino acids 65 and 74 of SEQ ID NO: 4;an epitope found between amino acids 115 and 124 of SEQ ID NO: 4;an epitope found between amino acids 127 and 136 of SEQ ID NO: 4;an epitope found between amino acids 143 and 152 of SEQ ID NO: 4;and a combination thereof; andwhen unmodified wild-type Ara h 3 protein has the amino acid sequence of SEQ ID NO: 6, the substitution is in an IgE epitope selected from the group consisting of: an epitope found between amino acids 33 and 47 of SEQ ID NO: 6;an epitope found between amino acids 240 and 254 of SEQ ID NO: 6;an epitope found between amino acids 279 and 293 of SEQ ID NO: 6;an epitope found between amino acids 303 and 317 of SEQ ID NO: 6;and a combination thereof:the expressed recombinant version of the food allergen protein being encapsulated within the dead E. coli cells, so that the encapsulated recombinant version of the food allergen protein is not exposed to the subject's IgE antibodies during administration; and a pharmaceutically acceptable carrier,so that one or more symptoms of the subject's allergy to the food allergen protein is reduced or decreased. 2. A method of treating peanut allergy in a subject susceptible to an anaphylactic allergic response to a peanut allergen protein, the method comprising a step of: administering to the subject via topical, oral, or local administration a composition comprising: dead E. coli cells that have expressed a non-secreted, recombinant version of a modified food allergen protein whose amino acid sequence differs from that of a corresponding wild-type food allergen protein in that at least one IgE epitope has a substitution in the modified food allergen protein such that the modified food allergen protein has a reduced ability to bind to or cross-link IgE as compared with unmodified wild-type food allergen protein, the at least one IgE epitope being one that is recognized when the unmodified wild-type food allergen protein is contacted with serum IgE from an individual that is allergic to the unmodified wild-type food allergen protein, wherein:when unmodified wild-type Ara h 1 protein has the amino acid sequence of SEQ ID NO: 2, the substitution is in an IgE epitope selected from the group consisting of: an epitope found between amino acids 25 and 34 of SEQ ID NO: 2;an epitope found between amino acids 48 and 57 of SEQ ID NO: 2;an epitope found between amino acids 65 and 74 of SEQ ID NO: 2;an epitope found between amino acids 89 and 98 of SEQ ID NO: 2;an epitope found between amino acids 97 and 106 of SEQ ID NO: 2;an epitope found between amino acids 107 and 116 of SEQ ID NO: 2;an epitope found between amino acids 123 and 132 of SEQ ID NO: 2;an epitope found between amino acids 134 and 143 of SEQ ID NO: 2;an epitope found between amino acids 294 and 303 of SEQ ID NO: 2;an epitope found between amino acids 311 and 320 of SEQ ID NO: 2;an epitope found between amino acids 325 and 334 of SEQ ID NO: 2;an epitope found between amino acids 344 and 353 of SEQ ID NO: 2;an epitope found between amino acids 393 and 402 of SEQ ID NO: 2;an epitope found between amino acids 409 and 418 of SEQ ID NO: 2;an epitope found between amino acids 461 and 470 of SEQ ID NO: 2;an epitope found between amino acids 498 and 507 of SEQ ID NO: 2;an epitope found between amino acids 525 and 534 of SEQ ID NO: 2;an epitope found between amino acids 539 and 548 of SEQ ID NO: 2;an epitope found between amino acids 551 and 560 of SEQ ID NO: 2;an epitope found between amino acids 559 and 568 of SEQ ID NO: 2;an epitope found between amino acids 578 and 587 of SEQ ID NO: 2;an epitope found between amino acids 597 and 606 of SEQ ID NO: 2;and a combination thereof; andwhen unmodified wild-type Ara h 2 protein has the amino acid sequence of SEQ ID NO: 4, the substitution is in an IgE epitope selected from the group consisting of: an epitope found between amino acids 15 and 24 of SEQ ID NO: 4;an epitope found between amino acids 21 and 30 of SEQ ID NO: 4;an epitope found between amino acids 27 and 36 of SEQ ID NO: 4;an epitope found between amino acids 39 and 48 of SEQ ID NO: 4;an epitope found between amino acids 49 and 58 of SEQ ID NO: 4;an epitope found between amino acids 57 and 66 of SEQ ID NO: 4;an epitope found between amino acids 65 and 74 of SEQ ID NO: 4;an epitope found between amino acids 115 and 124 of SEQ ID NO: 4;an epitope found between amino acids 127 and 136 of SEQ ID NO: 4;an epitope found between amino acids 143 and 152 of SEQ ID NO: 4;and a combination thereof; andwhen unmodified wild-type Ara h 3 protein has the amino acid sequence of SEQ ID NO: 6, the substitution is in an IgE epitope selected from the group consisting of: an epitope found between amino acids 33 and 47 of SEQ ID NO: 6;an epitope found between amino acids 240 and 254 of SEQ ID NO: 6;an epitope found between amino acids 279 and 293 of SEQ ID NO: 6;an epitope found between amino acids 303 and 317 of SEQ ID NO: 6;and a combination thereof:the expressed recombinant version of the food allergen protein being encapsulated within the dead E. coli cells; and a pharmaceutically acceptable carrier,so that one or more symptoms of the subject's allergy to the food allergen protein is reduced or decreased. 3. A method of treating peanut allergy in a subject susceptible to an anaphylactic allergic response to a food allergen protein, the method comprising a step of: administering to the subject via topical, oral, or local administration a composition comprising: dead E. coli cells that have expressed a recombinant version of a modified food allergen protein whose amino acid sequence differs from that of a corresponding wild-type food allergen protein in that at least one IgE epitope has a substitution in the modified food allergen protein such that the modified food allergen protein has a reduced ability to bind to or cross-link IgE as compared with unmodified wild-type food allergen protein, the at least one IgE epitope being one that is recognized when the unmodified wild-type food allergen protein is contacted with serum IgE from an individual that is allergic to the unmodified wild-type food allergen protein, wherein:when unmodified wild-type Ara h 1 protein has the amino acid sequence of SEQ ID NO: 2, the substitution is in an IgE epitope selected from the group consisting of: an epitope found between amino acids 25 and 34 of SEQ ID NO: 2;an epitope found between amino acids 48 and 57 of SEQ ID NO: 2;an epitope found between amino acids 65 and 74 of SEQ ID NO: 2;an epitope found between amino acids 89 and 98 of SEQ ID NO: 2;an epitope found between amino acids 97 and 106 of SEQ ID NO: 2;an epitope found between amino acids 107 and 116 of SEQ ID NO: 2;an epitope found between amino acids 123 and 132 of SEQ ID NO: 2;an epitope found between amino acids 134 and 143 of SEQ ID NO: 2;an epitope found between amino acids 294 and 303 of SEQ ID NO: 2;an epitope found between amino acids 311 and 320 of SEQ ID NO: 2;an epitope found between amino acids 325 and 334 of SEQ ID NO: 2;an epitope found between amino acids 344 and 353 of SEQ ID NO: 2;an epitope found between amino acids 393 and 402 of SEQ ID NO: 2;an epitope found between amino acids 409 and 418 of SEQ ID NO: 2;an epitope found between amino acids 461 and 470 of SEQ ID NO: 2;an epitope found between amino acids 498 and 507 of SEQ ID NO: 2;an epitope found between amino acids 525 and 534 of SEQ ID NO: 2;an epitope found between amino acids 539 and 548 of SEQ ID NO: 2;an epitope found between amino acids 551 and 560 of SEQ ID NO: 2;an epitope found between amino acids 559 and 568 of SEQ ID NO: 2;an epitope found between amino acids 578 and 587 of SEQ ID NO: 2;an epitope found between amino acids 597 and 606 of SEQ ID NO: 2;and a combination thereof; andwhen unmodified wild-type Ara h 2 protein has the amino acid sequence of SEQ ID NO: 4, the substitution is in an IgE epitope selected from the group consisting of: an epitope found between amino acids 15 and 24 of SEQ ID NO: 4;an epitope found between amino acids 21 and 30 of SEQ ID NO: 4;an epitope found between amino acids 27 and 36 of SEQ ID NO: 4;an epitope found between amino acids 39 and 48 of SEQ ID NO: 4;an epitope found between amino acids 49 and 58 of SEQ ID NO: 4;an epitope found between amino acids 57 and 66 of SEQ ID NO: 4;an epitope found between amino acids 65 and 74 of SEQ ID NO: 4;an epitope found between amino acids 115 and 124 of SEQ ID NO: 4;an epitope found between amino acids 127 and 136 of SEQ ID NO: 4;an epitope found between amino acids 143 and 152 of SEQ ID NO: 4;and a combination thereof; andwhen unmodified wild-type Ara h 3 protein has the amino acid sequence of SEQ ID NO: 6, the substitution is in an IgE epitope selected from the group consisting of: an epitope found between amino acids 33 and 47 of SEQ ID NO: 6;an epitope found between amino acids 240 and 254 of SEQ ID NO: 6;an epitope found between amino acids 279 and 293 of SEQ ID NO: 6;an epitope found between amino acids 303 and 317 of SEQ ID NO: 6;and a combination thereof:the expressed recombinant version of the food allergen protein being encapsulated within the dead E. coli cells, wherein the administered dead E. coli are taken up by antigen presenting cells in the subject, the recombinant version of the food allergen protein is released and processed inside the antigen presenting cells, and the processed protein is displayed on the antigen presenting cell surface; and a pharmaceutically acceptable carrier,so that one or more symptoms of the subject's allergy to the food allergen protein is reduced or decreased. 4. The method of any one of claims 1, 2, and 3, wherein in the step of administering, the recombinant version of the food allergen protein has a reduced number of IgE binding sites as compared to the unmodified wild-type food allergen protein. 5. The method of any one of claims 1, 2, and 3, wherein the topical administration is selected from the group consisting of nasal, pulmonary, and other mucosal routes.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (85)
Morgenstern Jay P. ; Konieczny Andrzej ; Bizinkauskas Christine B. ; Brauer Andrew W., Allergenic proteins and peptides from dog dander and use therefor.
Morgenstern Jay P. ; Bizinkauskas Christine B. ; Koniecsny Andrzej ; Brauer Andrew W., Allergenic proteins and peptides from dog dander and uses therefor.
Morgenstern Jay P. ; Konieczny Andrzej ; Bizinkauskas Christine B. ; Brauer Andrew W., Allergenic proteins and peptides from dog dander and uses therefor.
Breiteneder Heimo (Vienna ATX) Valenta Rudolf (Theresienfeld ATX) Breitenbach Michael (Vienna ATX) Kraft Dietrich (Vienna ATX) Rumpold Helmut (Vienna ATX) Scheiner Otto (Mariaenzersdorf ATX), Allergens of alder pollen and applications thereof.
Calenoff Emanuel (Burlingame CA) Jones Ruth M. (Los Altos CA) Tsay Yuh-Geng (San Jose CA) Scott John R. (Mountain View CA), Assaying allergen specific IgE levels with fluorogenic enzyme labeled antibody.
Valenta Rudolf (Theresienfeld ATX) Duchene Michael (Vienna ATX) Pettenburger Karin (Vienna ATX) Breitenbach Michael (Vienna ATX) Kraft Dietrich (Vienna ATX) Rumpold Helmut (Vienna ATX) Scheiner Otto , Birch pollen allergen P14 for diagnosis and therapy of allergic diseases.
Anderson David C. (Seattle WA) Morgan ; Jr. A. Charles (Edmonds WA) Abrams Paul G. (Seattle WA) Fritzberg Alan R. (Edmonds WA) Nichols Everett J. (Seattle WA), Covalently-linked complexes and methods for enhanced cytotoxicity and imaging.
Mark David F. (Danville CA) Lin Leo S. (Fremont CA) Yu Lu Shi-da (Oakland CA) Wang Alice M. (Walnut Creek CA), Cysteine-depleted muteins of biologically active proteins.
Gordon Julian (Arlesheim CHX) Hawkes Richard (Allschwil IL CHX) Niday Evelyn (Arlington Heights IL) Towbin Harry (Allschwil CHX), Devices and kits for immunological analysis.
Frankel Alan (21 Marinero Cir. #206 Tiburon CA 94920) Pabo Carl (18 Weldon Rd. Newton MA 02158) Barsoum James G. (9 Marlboro Rd. Lexington MA 02173) Fawell Stephen E. (One Black Horse Ter. Winchester, Fusion protein comprising tat-derived transport moiety.
Swain Philip A. ; Schad Victoria Carol ; Greenstein Julia Lea ; Exley Mark Adrian ; Fox Barbara Saxton ; Powers Stephen P. ; Gefter Malcolm L., Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same.
Le Page Richard William Falla,GBX ; Wells Jeremy Mark,GBX ; Wilson Peter William,GBX ; De Villareal Pamela Norton,GBX, Heterologous gene expression in lactococcus, and the expression products therefrom.
Metcalfe Dean D. (Bethesda MD) Martin Brian M. (Bethesda MD) Roa Pillarisetti V. S. (Bangalore INX), IgE-binding epitopes of a major heat-stable crustacean allergen derived from shrimp.
Jarvis ; Jr. Allan P. (Newburyport MA) Koch George A. (Medfield MA) Abrams Paul G. (Washington DC), Induction of immune response by immunization with encapsulated antigen-producing cells.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor.
Valenta Rudolf (Theresienfeld ATX) Duchene Michael (Vienna ATX) Pettenburger Karin (Vienna ATX) Breitenbach Michael (Vienna ATX) Kraft Dietrich (Vienna ATX) Rumpold Helmut (Vienna ATX) Scheiner Otto , Method of production of birch pollen allergen P14.
Frankel Alan (21 Marinero Cir. #206 Tiburon CA 94920) Pabo Carl (18 Weldon Rd. Newton MA 02158) Barsoum James G. (9 Marlboro Rd. Lexington MA 02173) Fawell Stephen E. (One Black Horse Ter. Winchester, Nucleic acid conjugates of tat-derived transport polypeptides.
Frankel Alan (21 Marinero Cir. Tiburon CA 94920) Pabo Carl (18 Weldon Rd. Newton MA 02158) Barsoum James G. (9 Marlboro Rd. Lexington MA 02173) Fawell Stephen E. (One Black Horse Ter. Winchester MA 0, Nucleic acids encoding and methods of making tat-derived transport polypeptides.
Michael J. Gabriel (Cincinnati OH) Litwin Allen (Cincinnati OH), Oral administration of immunologically active biomolecules and other therapeutic proteins.
A. Wesley Burks, Jr. ; J. Steven Stanley ; Gael Cockrell ; Nina E. King ; Hugh A. Sampson ; Ricki M. Helm ; Gary A. Bannon, Peanut allergens and methods.
Michael J. Gabriel (418 Chisholm Trail Cincinnati OH 45215) Pesce Amadeo J. (5769 Whitechapel Cincinnati OH 45236), Polypeptide active immunosuppressant fraction.
Michael Jacob G. (418 Chisholm Trail Cincinnati OH 45215) Pesce Amadeo J. (5769 White Chapel Dr. Cincinnati OH 45236), Polypeptide active pollen immunosuppressant fraction.
Rogers Bruce L. (54 Richardson Rd. Belmont MA 02178) Morgenstern Jay P. (322 Marlborough St. Boston MA 02116) Bond Julian F. (294 Commercial St. Weymouth MA 02188) Garman Richard D. (86 Clarendon Ave, Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I.
Holmgren Jan,SEX ; Sanches Castillo Joaquin,MXX, Recombinant systems for expression of cholera B-subunit with the aid of foreign promoters and/or leader peptides.
Wheatley Margaret A. (Arlington MA) Langer Robert S. (Somerville MA) Eisen Herman N. (Waban MA), System for delayed and pulsed release of biologically active substances.
Garman Richard D. ; Greenstein Julia L. ; Kuo Mei-chang ; Rogers Bruce L. ; Franzen Henry M. ; Chen Xian ; Evans Sean ; Shaked Ze'ev, T cell epitopes of the major allergens from dermatophagoides (house dust mite).
Saint-Remy Jean-Marie (Grez-Doiceau BEX) Lebrun Philippe (Namur BEX) Lebeque Serge (Brussels BEX) Masson Pierre L. (Brussels BEX), Treatment of allergy and composition therefor.
Cobon Gary Stewart,AUX ; Austen Rosemary Ann,AUX ; O'Donnell Ian Joseph,AUX ; Frenkel Maurice Joseph,AUX ; Kennedy William Peter Keith,AUX ; Savin Keith William,AUX ; Wagland Barry Maxwell,AUX, Vaccines against animal parasitic nematodes.
Bermudes, David Gordon, Protease inhibitor: protease sensitive expression system and method improving the therapeutic activity and specificity of proteins and phage and phagemids delivered by bacteria.
Bermudes, David Gordon, Protease inhibitor: protease sensitive expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.